Informace o projektu
HARMONY - Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology
(HARMONY)
- Kód projektu
- 116026
- Období řešení
- 1/2017 - 6/2023
- Investor / Programový rámec / typ projektu
-
Evropská unie
- Horizon 2020
- Innovative Medicines Initiative
- Fakulta / Pracoviště MU
-
Středoevropský technologický institut
- prof. RNDr. Šárka Pospíšilová, Ph.D.
- Mgr. Ivona Blaháková
- Mgr. Jana Bruknerová
- RNDr. Jitka Malčíková, Ph.D.
- Mgr. Michaela Pešová
- Mgr. Tomáš Reigl
- Ing. Jan Svatoň, MSc.
- Anastasiya Volakhava, M.Sc.
- Spolupracující organizace
-
Ludwig-Maximilians-Universität München
University of Cambridge
The University of York
Universität Ulm
Universita di Bologna
Newcastle University
Universidad de Navarra
Medizinische Universitaet Wien
Fundacio Privada Vall d'Hebron
Universita degli Studi di Torino
Universita degli Studi di Roma Tor Vergata
European LeukemiaNet (ELN) Foundation
European Hematology Association (EHA)
Erasmus Universitair Medisch Centrum Rotterdam
VIB
Amsterdam UMC, locatie VUmc
Goethe-Universität Frankfurt
Fundació Institut de Recerca Contra la Leucemia Josep Carreras
Instituto de Ciencias de la Salud de Castilla y León (ICSCYL)
- Odpovědná osoba Santiago Moralejo del Arco
HARMONY is a European network of excellence that captures, integrates, analyzes, and harmonizes big data from high-quality multidisciplinary sources with the purpose to unlock valuable knowledge on various important hematologic malignancies (HMs). With this, a more rapid detection of promising treatment strategies and adverse events will be made possible, while taking into account demographic changes, individual patients’ needs, as well as the need to define standard outcome measures for the HMs to be included HARMONY. By bringing together key stakeholders in the clinical, academic, patient, HTA (health technology assessment), regulatory, economical, ethical and pharmaceutical field HARMONY will: (i) rapidly capture the current status in treating HMs; (ii) define the areas of utmost need for improved patient management; (iii) redefine the treatment goals based in individualized risk assessments and outcome measures; (iv) aim at better characterizing HMs for improved treatment strategies; (v) identify novel treatment targets and drugs; (vi) foster the design, management and coordination of innovative clinical and pre-clinical studies; (vii) raise awareness of cost-effectiveness by pursuing precision medicine approaches; (viii) provide novel resources and algorithms to more rapidly advance innovative concepts of health care and patient management in the field of HMs.
Cíle udržitelného rozvoje
Masarykova univerzita se hlásí k cílům udržitelného rozvoje OSN, jejichž záměrem je do roku 2030 zlepšit podmínky a kvalitu života na naší planetě.
Publikace
Počet publikací: 1
2018
-
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation
Leukemia, rok: 2018, ročník: 32, vydání: 5, DOI